Pycnogenol
Also sold as: Pine Bark Extract
Best-in-class: Pycnogenol
A standardized pine bark extract with an unusually large trial base for a botanical — largely because it's a single patented extract, so the studies are actually comparable.
Pycnogenol quick facts
| Suggested dose | 50–150 mg daily. |
| How often | Daily |
| Who it's for | Endothelial and venous support; a reasonable adjunct alongside L-arginine or L-citrulline. |
Unusually well-studied for a branded botanical, with positive trials across endothelial function, venous edema, melasma and erectile function. The arginine-plus-pycnogenol combination has the strongest data of any supplement pairing for erectile function specifically. Expensive relative to grape seed extract, which is chemically similar and much cheaper — the branded trials are what you are paying for.
How Pycnogenol actually works
French maritime pine bark procyanidins increase eNOS expression and protect nitric oxide from degradation, improving flow-mediated dilation. They also stabilize capillary walls by inhibiting the enzymes that degrade collagen and elastin in vessel basement membrane, which is why the same ingredient appears in venous insufficiency, retinopathy and skin trials.
Where to get Pycnogenol
Find Pycnogenol on iHerb →The evidence for Pycnogenol
Graded by what exists behind each claim.
✅ Clinically validated
- Meta-analyses show improved endothelial function and modest blood pressure reduction.
- Randomized trials support improvement in chronic venous insufficiency symptoms — leg swelling and heaviness.
- Trials show reduced platelet aggregation and improved erectile function when combined with L-arginine.
📊 Correlative data
- Traditional use of pine bark by Indigenous North American peoples and, famously, the account of Jacques Cartier's crew recovering from scurvy on a bark and needle infusion in 1536. That was vitamin C rather than the proanthocyanidins, which is a useful reminder about attributing traditional outcomes to the wrong constituent.
🧪 Theoretical / extrapolated benefits
- Procyanidins are proposed to increase nitric oxide availability, which fits the vascular findings coherently.
How to read these tiers: they say how much human evidence exists, not how well something works — and ✗ flags harm, never a disappointing trial. How the evidence tiers work →
What Pycnogenol actually does
The extract is a polymer mixture, and the molecule that ends up doing the work is not in the bottle. French maritime pine bark extract is standardized to 65 to 75 percent procyanidins — oligomers of catechin and epicatechin from dimers up to chains of twelve or more — alongside phenolic acids and taxifolin. Oligomers above the dimer are too large to cross the intestinal epithelium intact.
Colonic bacteria depolymerize them into something absorbable, and that metabolite has a name. Gut microbiota convert procyanidins to delta-(3,4-dihydroxyphenyl)-gamma-valerolactone, labeled M1 in the pharmacokinetic literature, which appears in plasma hours after dosing and is measurable in urine Bayer 2024. M1 accumulates in macrophages and endothelial cells and is the strongest candidate for whatever systemic activity this extract has.
The proposed vascular mechanism is nitric oxide and enzyme inhibition rather than antioxidant scavenging. Constituents and metabolites stimulate endothelial nitric oxide synthase, inhibit angiotensin-converting enzyme in vitro, and inhibit matrix metalloproteinase-9 in cell systems. The venous-tone and edema claims rest on the last of those, through effects on capillary permeability.
There is a documented anti-inflammatory action at the transcription factor. Procyanidin metabolites inhibit nuclear factor kappa B activation and reduce interleukin-1 beta and cyclooxygenase-2 expression in stimulated cells, which is the mechanistic argument behind the osteoarthritis and inflammatory endpoints in the trial literature Weichmann 2024.
And there is a mechanism with no receptor at all, which is worth stating. Taxifolin and the free catechins are directly antioxidant in a cuvette. At the plasma concentrations achievable — nanomolar for parent compounds Bayer 2024 — that chemistry cannot be the mechanism, and any explanation of this extract that begins with free radical scavenging is describing a test tube.
Cell, rodent, human — and where it stops
This page has more randomized trials behind it than almost anything else in the catalog, and that is the problem rather than the recommendation.
The pharmacokinetics have now been characterized properly and they constrain everything. A review of the human pharmacokinetics establishes which constituents are measurable in plasma, over what time course, and that the microbial metabolite M1 rather than the administered procyanidins is what circulates Bayer 2024. Anybody reasoning from a procyanidin concentration in a dish is reasoning about an exposure that does not occur.
The trial literature is large, and its shape is the finding. A review of randomized, double-blind, placebo-controlled human clinical studies covers dozens of trials across venous insufficiency, osteoarthritis, asthma, cognitive function, skin, diabetes and endothelial function Weichmann 2024. Each is small, each uses a different marker, and independent replication of any single result is rare.
Where somebody pooled a defined endpoint the effect shrank. A systematic review and meta-analysis asking whether pine bark extract improves cardiometabolic risk factors found the answer more equivocal than the individual trials suggest Mohammadi 2025. That is the usual fate of a literature made of many small positive studies.
The obstacle to transfer is that most of the trial literature involves the manufacturer. The extract is a single proprietary product, most trials are conducted with company support, and independent replication is the exception. That does not make a result wrong; it means the usual correction for sponsorship applies, and it is why the independent trials matter more than their number suggests.
An independent trial is instructive here. A placebo-controlled crossover of botanical agents including French maritime pine bark in Gulf War Illness was run outside the manufacturer's program Donovan 2021, and the combination trial of L-arginine with this extract in erectile dysfunction Tian 2023 cannot attribute its effect to either component. Those two designs bracket the problem: independent trials are rare, and combination trials cannot answer the question.
Pycnogenol — which form, and does it matter
Pycnogenol is a trademark for one specific extract and the generic pine bark on a shelf is not it. The trial literature belongs to a standardized French maritime pine bark extract from Pinus pinaster with a defined procyanidin specification Weichmann 2024. Grape seed extract, generic pine bark from other species, and unstandardized bark powder are different procyanidin mixtures with different oligomer distributions.
The oligomer distribution is the specification that matters and no consumer label reports it. Effects depend on which chain lengths are present, because chain length decides both whether anything is absorbed intact and how efficiently gut bacteria depolymerize the rest Bayer 2024. Percent procyanidins constrains the total and says nothing about the distribution.
The exposure profile has two peaks and the second one is the interesting one. Catechin and taxifolin appear in plasma within roughly 30 minutes to 2 hours at nanomolar concentrations, with rapid glucuronidation and sulfation in the enterocyte and liver and renal clearance of the conjugates. The microbial metabolite M1 appears from about 6 hours and persists far longer, which is why chronic dosing produces a different exposure from a single dose and why the trials dose for weeks Bayer 2024.
That microbial step is the same lottery the urolithin page describes. Conversion capacity varies between people and falls after antibiotics, so two people on the same 100 mg capsule can have different systemic exposures for reasons neither of them can measure. No trial has stratified on it.
The dose range in the literature is wide and unexplained. Trials use anywhere from 40 mg to 360 mg a day, with 100 to 150 mg commonest, and no dose-ranging study establishes where the curve turns Weichmann 2024. A reader choosing a dose is choosing from a distribution of trial protocols rather than from a dose-response.
What would have to be true, and how you would know it was not
1. Predict a small change in an endothelial measure and predict it needs weeks. Predict a measurable improvement in flow-mediated dilation over 4 to 8 weeks at 100 to 150 mg a day in somebody with impaired baseline function, and much less in a healthy adult Weichmann 2024 Mohammadi 2025.
2. Predict the cardiometabolic markers move less than the individual trials suggest. Predict small or absent changes in lipid panel, HbA1c (hemoglobin A1c) and blood pressure at 12 weeks, because that is what pooling found Mohammadi 2025. Measure them and hold the product to the pooled estimate rather than to the best single trial.
3. The prediction that cuts against the product. Predict that an independent, adequately powered, non-manufacturer trial of a single indication returns a smaller effect than the sponsored literature Donovan 2021. A large independent replication confirming the effect sizes in the review would falsify this page's central caution and would be the most valuable study this extract could have.
4. Predict the microbial metabolite explains the non-responders. Predict that urinary M1 varies severalfold between people on the same dose, and that responders have higher M1 Bayer 2024. No trial has measured it alongside an outcome, which makes this a prediction rather than a finding.
5. Predict the combination trials cannot be split. Predict that a trial of this extract with L-arginine cannot attribute its effect Tian 2023, and that a factorial design would assign most of it to one arm. That design has not been run for any of the combinations this extract is sold in.
What nobody has tested yet
The independent replication is the missing study, and it is missing across every indication. Dozens of small trials with a single sponsor is a different evidence base from a handful of independent ones Weichmann 2024. One large independent trial in the best-supported indication would be worth more than another twenty small ones.
Nobody has stratified on the microbial converter. M1 is measurable Bayer 2024 and no trial has related it to response. That single addition to an existing protocol would explain most of the between-person variation and has not been made.
The dose-response has never been established. Trials span nearly an order of magnitude in daily dose with no systematic comparison Mohammadi 2025. Whether 40 mg does what 300 mg does is unknown, which is unusual for a product with this many trials.
And no outcome trial exists in any indication. Every endpoint in this literature is a marker, a symptom scale or a functional measure over weeks to months. Whether any of them translates into a clinical event has not been tested Weichmann 2024.
Pycnogenol — its own safety story, not its category's
Tolerability across the trial literature is good and the complaints are minor. Gastrointestinal upset, headache, dizziness and occasional nausea, generally mild and reduced by taking it with food Weichmann 2024. There is no established tolerable upper intake level.
The plausible interaction is antiplatelet and it is mechanistic. Procyanidins inhibit platelet aggregation in vitro and the extract has been studied for effects on platelet function, so adding it to aspirin, clopidogrel or an anticoagulant is an additive situation. Stopping two weeks before elective surgery costs nothing.
Immune stimulation is a documented mechanism and a specific caution. The extract has been reported to increase natural killer cell activity and to modulate cytokine production, which is a reason to raise it with a clinician in autoimmune disease and in anyone on an immunosuppressant after transplant.
The glucose effect is small and additive. Reductions in fasting glucose have been reported in diabetes trials Mohammadi 2025, which matters alongside insulin or a sulfonylurea rather than on its own.
Who this is not established for. Pregnancy and lactation, with no adequate data. Children, where trials exist in asthma and attention disorders but the safety base is thin. And anyone buying generic pine bark on the strength of this literature, which belongs to one standardized extract Weichmann 2024 Bayer 2024. Nothing here is medical advice or diagnosis, and these statements have not been evaluated by the Food and Drug Administration.
Sources read for this page
- Weichmann F. Pycnogenol French maritime pine bark extract in randomized, double-blind, placebo-controlled human clinical studies. Front Nutr 2024 · PMID 38757130
- Bayer J. Review of the pharmacokinetics of French maritime pine bark extract (Pycnogenol) in humans. Front Nutr 2024 · PMID 38757126
- Mohammadi S. Does supplementation with pine bark extract improve cardiometabolic risk factors? A systematic review and meta-analysis. BMC Complement Med Ther 2025 · PMID 39987124
- Tian Y. Efficacy of L-arginine and Pycnogenol in the treatment of male erectile dysfunction: a systematic review and meta-analysis. Front Endocrinol (Lausanne) 2023 · PMID 37908749
- Donovan EK. A Placebo-Controlled, Pseudo-Randomized, Crossover Trial of Botanical Agents for Gulf War Illness: Curcumin (Curcuma longa), Boswellia (Boswellia serrata), and French Maritime Pine Bark (Pinus pinaster). Int J Environ Res Public Health 2021 · PMID 33802272
How you would know if it worked
There is no blood test for this one. That is not a criticism — it is a fact about the effect, and it changes how you should judge it.
- What to watch: Start with the label, because this is the rare botanical where the brand is the evidence: the trial base belongs to one patented, standardized pine bark extract, and a generic pine bark capsule is not the studied material. Then pick one endpoint and only one — leg heaviness and calf circumference at a marked point for the venous claim, or nothing at all for the endothelial claim, because flow-mediated dilation is an ultrasound in a vascular lab.
- How long before it means anything: 8-12 weeks at 50-150 mg. Venous symptom trials in this class run on that scale, and the endothelial work is measuring something you cannot perceive at all, so there is no shorter honest window.
- What will fool you: The erectile-function result people have heard about came from combining this with L-arginine rather than from the bark alone, so a single-ingredient bottle is not testing the study being quoted at you. It also has antiplatelet activity, which means easier bruising is a pharmacological signal rather than proof the vascular claim is landing — and a reason to stop well before any surgery.
Run it one variable at a time. Starting three things in one week means a result you cannot attribute, which is the same as no result.
Pycnogenol — safety & side effects
- Well tolerated; GI upset, dizziness and headache.
- Mild antiplatelet activity and blood-glucose lowering — additive with anticoagulants and diabetes medication.
- Immunostimulant activity, so caution with autoimmune disease and immunosuppressants. Not established as safe in pregnancy or breastfeeding — not because harm is documented, but because these are the two populations systematically excluded from the trials. Absence of data is not reassurance.
Not medical advice. If you take prescription medication or have a diagnosed condition, check this against it with a pharmacist or doctor — pharmacists are underused and free.
- When to take it, and what to take it with
- Which form actually absorbs
- Who it's worth it for
- Best-in-class brand pick
- Coach Cam's stacks and notes
- Fasted or with food, and when in the day
- Morning or night, and why that window
- Around training, or deliberately away from it
- What it must not share a window with
Everything above is free and stays free. Skool is where it becomes a plan — Pycnogenol in an order, with the rest of what you're running.
Unlock in Skool — $10/mo →Bloodwork to run alongside Pycnogenol
Baseline first, then again at 8–12 weeks.
| Marker | What it’s watching for |
|---|---|
| ApoB (Apolipoprotein B) | Counts the particles that cause plaque — a normal LDL-C can hide risk |
| Lipoprotein(a) — Lp(a) | Genetic, largely unmodifiable, and worth knowing once in your life |
| hs-CRP (High-Sensitivity C-Reactive Protein) | The inflammatory half of cardiovascular risk |
| Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) | The standard baseline these are usually aimed at |
The Real Cardiovascular Risk panel covers these in one order — 9 markers, $187.60 with the discount applied.
Check results you already have → · All 103 markers A–Z
Pycnogenol — frequently asked questions
What is Pycnogenol?
A standardized pine bark extract with an unusually large trial base for a botanical — largely because it's a single patented extract, so the studies are actually comparable.
What is the suggested dose of Pycnogenol?
50–150 mg daily. This is a general reference for education only — statements have not been evaluated by the FDA and this is not medical advice.
Where can I find Pycnogenol dosing and the full breakdown?
The suggested dose and the full evidence — clinical, correlative and theoretical — are on this page. What's inside Skool is when to take it, which form actually absorbs, the brand worth buying and Coach Cam's stacks.
Where can I buy Pycnogenol?
Coach Cam sources Pycnogenol from vetted, top-rated brands on iHerb — use the buy link on this page.
Pycnogenol inside a finished plan
One arm of 2 Protocol Blueprints, free to read in full.
What Pycnogenol is used for
Pycnogenol appears under 4 goals in the goal router.
Related Cardiovascular supplements
Where this goes next
Pycnogenol is the delivery arm of this plan. The page above is the free breakdown of one compound; the plan it belongs to — the dosing, the order to correct things in, the week-by-week schedule and what to retest — is a lesson inside Skool.